NEW YORK, Sept. 24, 2015 /PRNewswire-USNewswire/ -- IVD tests that can detect cancer or determine if a treatment is appropriate are in demand according to Kalorama Information, and there are over two hundred significant companies providing tests to the lab market. Immunoassays, molecular tests, point-of-care tests and histology tests are among the approaches used to detect cancer. The market research publisher said the market for these tests is nearly six billion dollars. Cancer diagnostic test competitors are profiled in Kalorama Information's latest report, The World Market for Cancer Diagnostics, 6th Edition.
The report can be found at: http://www.kaloramainformation.com/redirect.asp?progid=87853&productid=9292184.
"Multiple test technologies provides opportunities for a fair number of companies in the market," said Bruce Carlson, Publisher of Kalorama Information. "A few operate in many tests segments, but most are specialist companies."
The traditional market for cancer diagnostic tests consists of centralized clinical laboratories, according to Kalorama Information, and these remain the most important customers for oncology IVD products. These consist of reference laboratories (such as Laboratory Corporation of America or LabCorp, Quest Diagnostics, and others), hospital laboratories, laboratories operated by health maintenance organizations (HMOs), and other centralized laboratories. These laboratories range from very high volume labs down to smaller labs.
Among the larger companies competing in this market are Abbott, Qiagen, Siemens, Roche, Hologic and bioMerieux. The companies market a variety of products for cancer diagnosis and treatment selection:
- Abbott offers cancer immunoassays on its ARCHITECT analyzer including AFP, CA 125, CA 15-3, CA 19-9, CEA, free PSA, HE-4, and total PSA, as well as other products.
- bioMérieux markets the VIDAS® and miniVIDAS® immunoassay analyzers for small to medium-sized laboratories. These analyzers have a reagent menu offering over 85 different immunoassays that include tumor markers, and more.
- Siemens offers tumor marker tests on its ADVIA Centaur Immunoassay System, including AFP, BR 27.29, CA 125II, CA 15-3. CA 19-9Calcitonin (in development) CEA, Free PSA, PSA, PSA Complexed and Serum HER-2/neu.
- Hologic offers multiple HPV tests. The Cervista HPV HR assay and Cervista HPV 16/18 assay are part of what the company refers to as its legacy business, which includes diagnostic tests marketed by Hologic before the acquisition of Gen-Probe in 2012.
- QIAGEN markets the Rotor-Gene Q MDx is FDA approved, and two cancer tests: therascreen EGFR RGQ PCR Kit and therascreen KRAS RGQ PCR Kit. Companion diagnostics also a focus of the company; Qiagen reported that it had more than 20 projects underway to co-develop and market companion diagnostics with leading pharmaceutical and biotechnology companies.
- Roche Molecular Diagnostics also offers PCR-based assays for detection of cancer gene mutations in formalin-fixed, paraffin-embedded tissue (FFPET). These include the cobas® 4800 BRAF V600 Mutation Test , the cobas® KRAS Mutation Test and the cobas® EGFR Mutation Test. Roche also offers several HPV tests.
In addition to a detailed list of products and company profiles, Kalorama Information's The World Market for Cancer Diagnostics, 6th Edition includes market sizing and forecasts for various cancer testing segments. The report can be found at: http://www.kaloramainformation.com/redirect.asp?progid=87853&productid=9292184.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
Logo - http://photos.prnewswire.com/prnh/20150831/262422LOGO
Contact:
Bruce Carlson
(212) 807-2622
[email protected]
www.KaloramaInformation.com
SOURCE Kalorama Information
Share this article